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The high childhood mortality and life-long complications associated with sickle cell anemia
(SCA) in developing countries could be significantly reduced with effective prophylaxis and
education if SCA is diagnosed early in life. However, conventional laboratory methods used
for diagnosing SCA remain prohibitively expensive and impractical in this setting. This study
describes the clinical validation of a low-cost paper-based test for SCA that can accurately
identify sickle trait carriers (HbAS) and individuals with SCA (HbSS) among adults and chil-
dren over 1 year of age.
Methods and Findings
In a population of healthy volunteers and SCA patients in the United States (n = 55) the test
identified individuals whose blood contained any HbS (HbAS and HbSS) with 100% sensi-
tivity and 100% specificity for both visual evaluation and automated analysis, and detected
SCA (HbSS) with 93% sensitivity and 94% specificity for visual evaluation and 100% sensi-
tivity and 97% specificity for automated analysis. In a population of post-partum women
(with a previously unknown SCA status) at a primary obstetric hospital in Cabinda, Angola
(n = 226) the test identified sickle cell trait carriers with 94% sensitivity and 97% specificity
using visual evaluation (none of the women had SCA). Notably, our test permits instrument-
and electricity-free visual diagnostics, requires minimal training to be performed, can be
completed within 30 minutes, and costs about $0.07 in test-specific consumable materials.
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Conclusions
Our results validate the paper-based SCA test as a useful low-cost tool for screening adults
and children for sickle trait and disease and demonstrate its practicality in resource-limited
clinical settings.
Introduction
Sickle cell anemia (SCA) is the most severe and prevalent form of sickle cell disease, accounting
for more than 80% of all affected births worldwide.[1, 2] SCA results from homozygous inheri-
tance of a missense mutation that induces a single amino acid change in the β-globin subunit
of adult hemoglobin, converting normal adult hemoglobin (HbA) into sickle hemoglobin
(HbS). Other less common forms of sickle cell disease occur when HbS is co-inherited with
hemoglobin C (HbSC disease), β-thalassemia (HbSβ-thalassemia), or other abnormal hemo-
globins. As a result of the mutation, the molecules of HbS gain the ability to polymerize into
long fibers under hypoxic conditions, inducing a number of structural and functional abnor-
malities in affected erythrocytes. The cumulative effect of these abnormalities is an increased
propensity of sickle erythrocytes to undergo intravascular lysis or trigger episodic occlusion of
blood vessels. These abnormalities in turn result in systemic ischemia-reperfusion injury,
chronic inflammation, activation of the coagulation system, and vascular dysfunction that
induce the various clinical manifestations of SCA, giving rise to life-long morbidity and prema-
ture mortality associated with the disease.[3]
Children under 5 years of age are at increased risk of death from infections and other life-
threatening complications of SCA, most of which can be prevented through highly effective
and inexpensive prophylaxis (e.g. prophylactic administration of penicillin, pneumococcal
immunizations, distribution of malaria bed nets, and education of parents about the impor-
tance of seeking medical attention for fever) if SCA is diagnosed early in life.[4, 5] SCA is
normally diagnosed by measuring the HbS content (%HbS) in blood of patients with high-per-
formance liquid chromatography (HPLC)[6], hemoglobin electrophoresis (HE)[7] or isoelec-
tric focusing (IEF)[8]. Universal screening of newborns in the United States and many other
developed countries using these highly accurate laboratory methods has enabled early interven-
tion and treatment of SCA, which have significantly reduced SCA-related early childhood mor-
tality and have contributed to the overall improvement in the quality of life and life-span of
adults with SCA.[9, 10]
Although prevalent worldwide due to population migration, SCA is most common in sub-
Saharan Africa where more than 200,000 affected births occur every year. Recent data from a
newborn screening program in Angola, for example, indicates incidence at birth of approxi-
mately 21% for sickle trait (HbAS) and approximately 1.5% for SCA (HbSS).[11, 12] Estimates
suggest that as many as 50–90% of the children born with SCA in low-income developing
countries of sub-Saharan Africa will die before the age of 5.[13, 14] Universal newborn screen-
ing using existing technologies may not be currently feasible in these settings because of the
large number of out-of-hospital births,[15] prohibitively high cost of laboratory methods
needed for screening newborns, and logistical constraints associated with contacting parents of
affected infants for counseling and preventive care after postnatal discharge. For similar rea-
sons, there have been few population-wide estimates of the prevalence of SCA or attempts to
screen for carriers of sickle trait for purposes of genetic counseling. An alternative approach to
identifying and establishing care for SCA patients would be to screen older infants at routine
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postnatal medical visits, or via large-scale outreach efforts since major complications are rare
in the first six months of infancy.[16] The development and validation of a simple, rapid, and
inexpensive screening test for SCA would represent a significant advance that could transform
clinical care for this disease in low-income developing countries.
Our research laboratory has recently developed an easy-to-use, inexpensive, rapid test for
SCA that could accurately identify normal individuals (HbAA), sickle trait carriers (HbAS)
and individuals suffering from SCA (HbSS) in a population of adults and children over one
year of age. Our test operates via visual interpretation of the blood stain patterns produced on
chromatography paper by a drop of blood mixed with a hemoglobin (Hb) solubility buffer due
to the difference in transport of insoluble sickle hemoglobin (HbS) and soluble forms of hemo-
globin (HbA, HbF, HbC) through the paper substrate.[17–19] In this manuscript, we describe
further development of the paper-based test and its initial clinical validation for identifying
individuals with sickle cell trait (HbAS), sickle cell anemia (HbSS) and other forms of sickle
cell disease (HbSC, HbSβ- thalassemia) in our research laboratory in the United States. Fur-
thermore, we demonstrate the utility of the paper-based test in resource-limited settings by
evaluating its diagnostic accuracy for screening post-partum women with previously unknown
SCA status for sickle cell trait or disease in a clinical laboratory of the sickle cell screening pro-
gram in Cabinda, Angola.
Materials and Methods
Blood samples (New Orleans, Louisiana, United States)
Venous blood samples were obtained with written informed consent in 4mL Vacutainer tubes
(K2EDTA, BD, Franklin Lakes, NJ) from healthy volunteers and patients of the Pediatric
Hematology- Oncology Clinic (Tulane University Hospital) and the Sickle Cell Center of
Southern Louisiana (New Orleans, LA). Samples from patients who received blood transfu-
sions in the previous three months were excluded. Blood samples were kept at room tempera-
ture (20–25°C) following collection by venipuncture and used within 4–5 hours after
venipuncture. The hemoglobin content of blood samples from sickle cell trait carriers and
sickle cell disease patients was quantified via hemoglobin electrophoresis at the Children’s Hos-
pital of Oakland Research Laboratory (Oakland, CA). A total of 55 patients were included in
the United States study population. The study protocol was approved by Tulane University
Biomedical Institutional Review Board.
Blood samples (Cabinda, Angola)
Blood samples were obtained with written informed consent from post-partum mothers of
unknown sickle cell status at the Primero de Maio obstetric hospital (Cabinda, Angola). Capil-
lary blood samples were collected by finger-stick into K2EDTA coated collection tubes
(Microvette, Sarstedt AG & Co., Germany) and onto paper cards (Whatman™ 903 Neonatal
Screening Protein Saver Cards, GE Healthcare, USA). Subsequent testing on these samples was
performed at the newborn screening laboratory of the Clinica de Celulas Falciformes at the
Dispensario Materno Infantil in Cabinda. Blood spots on paper cards were allowed to dry
completely before being used for isoelectric focusing (IEF) electrophoresis to qualitatively
determine the presence of hemoglobin variants. Liquid blood samples were refrigerated follow-
ing collection and used within 21 days after collection for the rapid SCA diagnostic test. A total
of 226 patients were included in the Angola study population. This part of research was
approved by the Ethics Committee of the Scientific Council of the Faculty of Medicine, Univer-
sidad 11 de Noviembre (Cabinda, Angola), and by the Institutional Review Board for Human
Subject Research for Baylor College of Medicine and Affiliated Hospitals.
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Hemoglobin solubility buffer
The hemoglobin solubility buffer used in this study consisted of three components: saponin,
sodium hydrosulfite and a concentrated phosphate buffer.[17, 18] Potassium phosphate buffer
at 2.49M was made by dissolving solid 1.24M (169 g/L) monobasic and 1.25M (217 g/L) dibasic
potassium phosphate in deionized water (final concentration of 2.49M). Saponin (4g/L) irre-
versibly lyses red blood cells (RBCs) by creating holes in the lipid bilayer, thereby releasing
hemoglobin into the buffer.[20] Sodium hydrosulfite (30 g/L) then converts the released hemo-
globin into deoxy-Hb that is either soluble (HbA, HbE, HbF or HbC) or insoluble (HbS) in the
phosphate buffer.[21, 22] Saponin and sodium hydrosulfite were stored as dry reagents and
concentrated phosphate buffer was stored as an aqueous solution. Hemoglobin solubility buffer
was reconstituted at the site where the tests were performed, stored at ambient temperature
and used within 1 day. For additional information on optimization of the Hb solubility buffer
and stability of the assay please see S1 and S2 Figs.
Automated scoring of the blood stain patterns
The sheets of paper containing an array of dried blood stains were digitized with a portable flat-
bed scanner (CanoScan LiDE110, Canon USA Inc, Lake Success, NY) and the scanned images
were analyzed with a custom image analysis algorithm (MATLAB, The Math Works Inc,
Natick, MA). The quantitative blood stain pattern analysis was based on the RGB values of the
digitized images. The color data from the Blue (B) channel of each pixel was used to quantify
the red color intensity of multiple sections of the blood stain (<color intensity> =<255 –B>).
S-index was defined as the quotient of mean red color intensity of pixels in the center area of
the blood stain and mean color intensity of pixels in the ring area of the blood stain. The S-
index represents the ratio of HbS (insoluble when deoxygenated in concentrated phosphate
buffer) to other (soluble) forms of hemoglobin present in the sample. C-index was defined as
the product of the total red color intensity of the dark red center spot and the average red color
intensity at a distance of 5 mm from the center of the blood stain. The C-index represents the
amount of HbS and the total amount of Hb present in the sample.
Evaluation of test performance
Sensitivity = TP / (TP + TN); specificity = TN / (FP + TN); positive predictive value (PPV) = TP /
(TP + FP); negative predictive value (NPV) = TN / (TN + FN); and accuracy = (TP + TN) / (TP +
FP + TN + FN) were calculated; where TP = true positive, FP = false positive, TN = true negative
and FN = false negative. 95% confidence intervals were calculated using the Wilson method.
[23] Receiver operating characteristic (ROC) curves were created using a custom algorithm
(MATLAB, The Math Works Inc, Natick, MA). Fleiss’ kappa was calculated to determine
inter-operator agreement for visual diagnoses.[24]
Results
Visual diagnosis of sickle cell trait and sickle cell anemia with the paper-
based test
We described the design and operation of the paper-based SCA test previously.[17, 18] Briefly,
to perform the test a sample of blood is diluted with the hemoglobin solubility buffer (see S1
Methods) at a 1:10 ratio (by volume) and then a 20 μL droplet of this mixture is deposited onto
chromatography paper (Fig 1A). The insoluble polymerized deoxy-HbS and cellular debris are
entangled by the paper fibers, remaining within the original outline of the droplet deposited on
paper while soluble forms of hemoglobin are transported laterally outwards by capillary action.
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This process produces a blood stain with an easily recognizable pattern of red color intensity
representative of the Hb content of the blood sample (Fig 1B).[18]
We hypothesized that the characteristic differences between the patterns of blood stains
produced by samples from individuals with normal Hb expression (HbAA), sickle cell trait car-
riers (HbAS) and sickle cell anemia patients (HbSS) (Fig 1B) would permit conclusive identifi-
cation of subjects of each type by visual classification. We tested this hypothesis using venous
blood samples from healthy volunteers and from patients and parents of the Pediatric Hema-
tology-Oncology Clinic (Tulane University Hospital) and the Sickle Cell Center of Southern
Louisiana (New Orleans, LA) under an approved IRB protocol. Our study population included
children age 12 months and older and adults (n = 55), with hemoglobin concentrations ranging
from 6.2 to 16.5 g/dL, HbS levels ranging from 0 to 93% and HbF levels ranging from 0 to 28%.
Five novice users independently scored blood stains (presented in a randomized order) from
HbAA (n = 18), HbAS (n = 17) and HbSS (n = 20) blood samples as HbAA, HbAS or HbSS.
Fig 2A shows the aggregate confusion matrix of the visual diagnoses made by all scorers. The
paper-based SCA test was able to detect the presence of any HbS in a sample (i.e., distinguish
HbAS and HbSS from HbAA) with mean sensitivity of 100% (SD, standard deviation = 0%)
and specificity of 100% (SD = 0.0%). The test was able to identify HbSS samples (i.e., distin-
guish HbSS from HbAS and HbAA) with sensitivity of 93.0% (SD = 7.5%) and specificity of
93.7% (SD = 2.8%). The test was able to distinguish HbSS samples from HbAS samples with
sensitivity of 93.0% (SD = 7.5%) and specificity of 87.1% (SD = 5.8%). Table 1 contains a sum-
mary of the mean and standard deviation of other performance metrics for diagnoses made via
visual evaluation of the rapid paper-based test. The Fleiss’ kappa calculated for all scored
Fig 1. Overview of the paper-based SCA diagnostic test. (a) To perform the test, a 20 μL droplet of blood
mixed 1:10 (by volume) with Hb solubility buffer–a concentrated phosphate buffer (2.49M) containing a
hemolytic (saponin) and a reducing agent (sodium hydrosulfite)–was deposited on paper. Differential
transport of polymerized HbS and soluble forms of Hb in the paper substrate produced blood stains with
characteristic patterns. (b) Representative images of the blood stain patterns produced by HbAA, HbAS and
HbSS samples.
doi:10.1371/journal.pone.0144901.g001
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Fig 2. Validation of the paper-based SCA test in a research laboratory and in a resource-limited
clinical setting (Cabinda, Angola). (a) Aggregate confusion matrix for the diagnoses of blood samples
collected from normal volunteers and patients of Pediatric Hematology-Oncology Clinic at Tulane University
Hospital and of the Sickle Cell Center of Southern Louisiana (New Orleans, LA) performed via visual
evaluation of the blood stains by human scorers (n = 5). Rows correspond to true genotypes (diagnosed by
hemoglobin electrophoresis) and columns correspond to predicted genotypes (diagnosed by the paper-
based test). Shaded cells along the diagonal contain numbers of correct diagnoses. (b) Confusion matrix for
the diagnoses of blood samples collected at the Primero de Maio obstetric hospital from postnatal females
with unknown SCA status. The rapid test was performed and interpreted via visual evaluation by healthcare
workers at the newborn screening laboratory of the Clinica de Celulas Falciformes at the Dispensario
Paper-Based Screening Test for Sickle Cell Anemia
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images was 0.91, suggesting an almost perfect agreement between the five scorers in reading
the presented test stains.
Validation of the paper-based SCA test in a resource-limited setting
The sickle cell newborn screening program in Cabinda, Angola currently collects blood sam-
ples from neonates born at the Primero de Maio obstetric hospital for early diagnosis by iso-
electric focusing (IEF) gel electrophoresis. We reasoned that the mothers of these babies
presented an easily accessible population in which to assess the feasibility and diagnostic accu-
racy of our paper-based SCA screening test, particularly since we could concurrently perform
IEF analysis for determination of their exact sickle cell status.
Two healthcare workers at the Cabinda sickle cell newborn screening laboratory (who had
no prior experience with the test) were trained to collect samples of capillary blood from these
subjects via finger prick, process them using the paper-based test, and score them visually as
either HbAA, HbAS, or HbSS. A total of 276 subjects were enrolled on the study from the 400
eligible mothers seen at the hospital during this recruitment phase, and 226 samples were suc-
cessfully processed and independently scored with both the paper-based SCA test and IEF elec-
trophoresis (S5 Fig). Fig 2B shows the confusion matrix of the visual diagnoses made by the
health workers. The paper-based SCA test was able to detect the presence of any HbS in the
sample (i.e., distinguish HbAS and HbSS from HbAA subjects) with sensitivity of 94.2% (95%
confidence interval, CI: 90.4–96.6%), specificity of 97.7% (CI: 94.8–99.0%), positive predictive
value of 92.5% (CI: 88.3–95.2%), negative predictive value of 98.3% (CI: 95.6–99.3%) and over-
all diagnostic accuracy of 96.9% (CI: 93.7–98.5%). Additionally, we found that none of the
post-partum women in our study had HbSS, likely due to our relatively small sample size, the
decreased prevalence of SCA in the adult population due to early mortality, and the low likeli-
hood of a woman with SCA carrying a baby to term without intensive prenatal care in that
setting.
Automated diagnostics of sickle cell trait and sickle cell anemia with the
paper-based test
Optionally, once the newly formed blood stain dries out completely (<25 minutes at 18–22°C
room temperature and 20–80% humidity), the sheet of chromatography paper containing an
array of such blood stains can be digitized using a portable flatbed scanner.[17, 18] To permit
Materno Infantil (Cabinda, Angola). Rows correspond to true genotypes (diagnosed by isoelectric focusing)
and columns correspond to predicted genotypes (diagnosed by the paper-based test). Shaded cells along
the diagonal contain numbers of correct diagnoses.
doi:10.1371/journal.pone.0144901.g002
Table 1. Visual diagnosis performance metrics.
AA vs (AS and SS) SS vs (AA and AS) AS vs SS
Sensitivity 100.0 ± 0.0% 93.0 ± 7.5% 93.0 ± 7.5%
Speciﬁcity 100.0 ± 0.0% 93.7 ± 2.8% 87.1 ± 5.8%
PPV 100.0 ± 0.0% 89.8 ± 3.8% 89.8 ± 3.8%
NPV 100.0 ± 0.0% 96.2 ± 3.9% 92.4 ± 7.5%
Accuracy 100.0 ± 0.0% 93.5 ± 1.5% 90.3 ± 2.2%
Summary of performance metrics for visual diagnoses made by different scorers (n = 5) on blood samples obtained from healthy subjects and SCD
patients in New Orleans, LA. Mean values ± SD.
doi:10.1371/journal.pone.0144901.t001
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quantitative and automated scoring of samples, we developed a custom image analysis algo-
rithm (implemented in MATLAB) to calculate an S-index from the digitized blood stains. We
defined S-index as the quotient of mean red color intensity of pixels in the center area of the
blood stain and mean color intensity of pixels in the ring area of the blood stain (Fig 3A).
Because the mean color intensity of the center spot is proportional to the amount of HbS (ren-
dered insoluble by the hemoglobin solubility buffer), and the mean color intensity of the
peripheral ring is proportional to the amount of soluble forms of hemoglobin (HbA, HbF and
HbC), the S-index represents the fraction (or percentage) of HbS in the total hemoglobin con-
tent of the sample. The concentration of hemoglobin (inclusive of all hemoglobin variants) in
the sample droplet determines the overall brightness of the blood stain produced on paper, and
Fig 3. Automated analysis of blood stains in paper. (a) A custom image analysis algorithm automatically detected the center of each blood stain (dashed
crosshair) and extracted the RGB values for all pixels contained within the dark red center spot (smaller dashed circle) and within the pink peripheral ring
(area between the smaller and the larger dashed circles). The S-index was defined as the quotient of the mean red color intensity of the center spot and that
of the peripheral ring of the blood stain. (b) The values of the S-index for (●) HbAA (n = 18), (♦) HbAS (n = 17) and (■) HbSS (n = 20) samples obtained from
healthy subjects and patients in New Orleans, LA. (c) Receiver operating characteristic (ROC) curves for the use of S-index to identify HbAA, HbAS and
HbSS samples. The area under the curve (AUC) for discriminating HbAA from HbAS and HbSS was 1.00, the AUC for discriminating HbSS from HbAA and
HbAS was 0.9986 and the AUC for discriminating HbSS from HbAS was 0.9971.
doi:10.1371/journal.pone.0144901.g003
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may vary significantly due to variation of blood hemoglobin among subjects and imperfections
of the sample preparation protocol. Although variations in hemoglobin concentration change
the absolute values of the mean color intensity of the center spot and the peripheral ring, they
do not affect the value of S-index, which is calculated as a quotient of the two color intensities.
[17, 18]
Fig 3 demonstrates the ability of the S-index to differentiate between HbAA, HbAS and
HbSS blood samples in the same cohort in the United States used for the visual scoring
described above. Using the S-index, our paper-based SCA test was able to detect the presence
of any HbS in the sample (i.e., distinguish HbAS and HbSS from HbAA) with sensitivity of
100% (CI: 93.5–100.0%) and specificity of 100% (CI: 93.5–100.0%) (Fig 3B). The test was able
to identify HbSS samples (i.e., distinguish HbSS from HbAS and HbAA) with sensitivity of
100% (CI: 93.5–100.0%) and specificity of 97.1% (CI: 88.8–99.3%) (Fig 3B). The test was able
to distinguish HbSS samples from HbAS samples with sensitivity of 100% (CI: 90.6–100.0%)
and specificity of 94.1% (CI: 81.6–98.3%) (Fig 3B). Fig 3C shows the receiver operating charac-
teristic (ROC) curves for the use of S-index to identify HbAA, HbAS and HbSS samples. Based
on the data from n = 55 subjects, the area under the curve (AUC) for discriminating HbAA
from HbAS and HbSS was 1.00, the AUC for discriminating HbSS from HbAA and HbAS was
0.9986 and the AUC for discriminating HbSS from HbAS was 0.9971 (Fig 3C). Table 2 con-
tains a summary of the mean and standard deviation of other performance metrics for diagno-
ses made via automated evaluation of the rapid paper-based test.
Using the paper-based SCA test for diagnosing other forms of sickle cell
disease
The easily distinguishable patterns of blood stains produced by HbAA, HbAS, and HbSS sam-
ples on paper enabled direct and relatively straightforward diagnostics (Fig 1B). We could not,
however, visually distinguish between HbAS and HbSC samples (Fig 4A) or between HbSS
and HbSβ+-thalassemia samples (Fig 4B). Similarly, in automated analysis based on S-index
HbSβ+-thalassemia samples (n = 3) were indistinguishable from samples in the HbSS group
because of the high HbS content in both sets of samples (> 60% HbS for HbSβ+-thalassemia)
(Fig 4C). Likewise, HbSC samples (n = 16) grouped very closely with HbAS samples because of
the relatively small difference between their HbS content (38–42% for HbAS and 41–50% for
HbSC subjects in this study) (Fig 4C).
To address this limitation (the inability of the paper-based test to accurately differentiate
HbAS and HbSC samples) we devised an alternative metric dubbed C-index, which was
defined as the product of total red color intensity of all pixels in the center area of the blood
stain and average red color intensity of all pixels at a distance of 5 mm from the center of the
Table 2. Automated diagnosis performance metrics.
AA vs (AS and SS) SS vs (AA and AS) AS vs SS
Sensitivity 100% 100% 100%
Speciﬁcity 100% 97% 94%
PPV 100% 95% 95%
NPV 100% 100% 100%
Accuracy 100% 98% 97%
Summary of performance metrics for automated diagnoses made by the image analysis algorithm on blood
samples obtained from healthy subjects and SCD patients in New Orleans, LA.
doi:10.1371/journal.pone.0144901.t002
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blood stain. The C-index takes into account the absolute concentration of Hb present in the
sample, unlike the S-index which is based on only the relative concentrations of HbS and other
forms of Hb. The inclusion of absolute Hb concentration in the calculation of the C-index
enables it to distinguish between HbSC and HbAS because HbSC samples typically have lower
Hb concentrations that HbAS samples. The C-index was able to differentiate HbSC from
HbAS samples (Fig 5) with sensitivity of 100% (CI: 89.6–100.0%) and specificity of 59.0% (CI:
42.2–74.0%). In the ROC analysis, the AUC for the use of S-index to differentiate HbSC and
HbAS was 0.67, and the AUC for the use of C-index was 0.82 (and the AUC for the use of %
HbS data measured by Hb electrophoresis to distinguish HbSC from HbAS was 0.99).
Discussion
Population-wide screening for SCA using conventional diagnostic methods (e.g., HE, IEF or
HPLC) is currently impractical because of the prohibitively high cost and lack of access to the
technical infrastructure required for such testing. A more feasible approach, given the limited
resources available for healthcare in low-income developing countries and the relatively low
incidence of the disease in the general population (e.g., ~21% sickle cell trait and ~1.5% sickle
cell anemia at birth in Angola),[11, 12] could be to use a low-cost screening assay with a low
false-negative rate for general population screening, and then perform high-cost laboratory
testing to confirm the diagnosis only for ambiguous cases.
In this paper, we present the initial clinical validation of the paper-based SCA assay we engi-
neered previously to enable such an approach. Our assay, which relies on the differential wick-
ing of insoluble sickle Hb and soluble non-sickle Hb in paper, is capable of distinguishing
HbSS and HbAS samples from each other and from samples free of sickle Hb with a high
degree of accuracy and reproducibility. Our test can identify individuals whose blood contains
Fig 4. Diagnosis of other forms of sickle cell disease. (a) Representative images of blood stains produced in paper by HbSC samples and by HbAS
samples, for comparison. (b) Representative images of blood stains produced in paper by HbSβ+-thalassemia samples and by HbSS samples, for
comparison. (c) Classification of HbSC and HbSβ+-thalassemia samples in the S-index domain. The values of the S-index for () HbAA, HbAS and HbSS
samples (n = 55), (■) HbSC (n = 16) and (♦) HbSβ+-thalassemia (n = 3) are shown on Y-axis. The location along the X-axis of each data point for HbAS,
HbSS, HbSC and HbSβ+-thalassemia samples corresponds to their %HbSmeasured with Hb electrophoresis by an off-site clinical laboratory. HbAA
samples (n = 18) contained no HbS; hence the random lateral spread of the data points representing these samples on the plot.
doi:10.1371/journal.pone.0144901.g004
Paper-Based Screening Test for Sickle Cell Anemia
PLOS ONE | DOI:10.1371/journal.pone.0144901 January 6, 2016 10 / 17
any HbS with 94.2% sensitivity and 97.7% specificity via visual classification of the blood stains
(and with 100% sensitivity and 100% specificity via automated analysis). Such diagnostic accu-
racy approaches that of much more technologically complex methods.
Our paper-based SCA test also offers a number of advantages that are highly relevant in
resource-limited settings. It is simple and rapid to use, requiring only three steps for comple-
tion and permitting reliable visual scoring of results within 30–40 minutes of sample collection.
This simplicity also makes the test portable for use in outlying facilities where standard labora-
tory equipment may not be available and distance, turn-around time, and poor communication
infrastructure can limit the usefulness of screening outreach.
The cost of test-specific reagents and materials for the paper-based test is $0.07 per test (S1
Table). The cost of materials necessary to collect and meter blood (typically not packaged with
commercially available test kits or included in per-test cost estimates) is about $0.70. The total
per-test cost for all components necessary to perform the paper-based test is therefore $0.77
(for a detailed cost breakdown see S1 Table). Samples can be processed individually or in
batched lots without significantly affecting the per-test costs. The cost of optional equipment
(i.e., laptop and portable scanner) to perform automated analysis of blood stains is less than
$400. In contrast, the estimated per-test cost for conventional IEF and HPLC at our collaborat-
ing clinical center in the United States is approximately $60, and the estimated cost per sample
for IEF testing in the recently established newborn screening program in Angola is $4.94 when
samples are batched in large lots.[11, 18] Additionally, these conventional methods require
specialized equipment and trained technicians, representing large initial investments for each
new testing site. As such, the rapid test offers significant cost saving advantages compared to
other methods of SCA diagnosis.
The paper-based test also has the virtue of being relatively insensitive to variations in sample
storage, lysate preparation, and stain development and storage (see S3 and S4 Figs). Although
we did not systematically test the effect of temperature and humidity on performance of the
Fig 5. Differentiation of HbSC samples from HbAS samples via automated image analysis. (a) The values of S-index for HbAS (n = 17) and HbSC
(n = 16) samples. (b) Vertical scatter plots of C-index (normalized by cutoff values) for HbAS and HbSC samples. C-index was defined as the product of total
color intensity of all pixels in the center area of the blood stain and average color intensity of all pixels at a distance of 5 mm from the center of the blood stain.
(c) ROC curves for differentiating HbSC and HbAS based on (-) S-index, AUC = 0.67; (-) C-index, AUC = 0.82; and (-) %HbS by electrophoresis, AUC = 0.99.
doi:10.1371/journal.pone.0144901.g005
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test, during this study the temperature in our research laboratory in the United States and in
the clinical laboratory in Cabinda, Angola varied from 20 to 30°C and humidity varied from 20
to 90% without a noticeable effect on the assay performance. These observations suggest that
our paper-based SCA assay is reasonably stable with respect to various environmental chal-
lenges. Finally our results obtained in Cabinda indicate that the paper-based assay is practical
and feasible in a resource-limited setting and can be performed and interpreted by healthcare
workers in such settings after only a few hours of informal training.
Our paper-based SCA test represents a significant improvement over existing assays based
on Hb solubility (e.g., SickleDexTM). These assays allow the operator to visually confirm the
presence of HbS within a sample, but, unlike our paper-based test, cannot distinguish between
sickle trait and disease. Various modifications of the standard hemoglobin solubility assay that
enable differentiation of sickle trait from disease rely on complex sample preparation proce-
dures involving additional laboratory equipment and analytical instruments for detection,[25–
27] and therefore have limited applicability in resource-limited settings of low-income devel-
oping countries.
Tests based on sickling of intact RBCs require relatively complex and expensive equipment
such as a conventional microscope or a smartphone equipped with a microscope attachment to
make the observation, and even then have difficulty to accurately distinguish sickle trait from
disease because both types of samples contain at least some sickled cells. Recent advances in
the field of microfluidics have produced an array of highly innovative research tools that can
distinguish flow patterns of sickle and non-sickle blood samples.[28] These microfluidic
devices, however, are largely impractical as low-cost diagnostic tools because of their complex-
ity, very high cost, need for highly skilled personnel and a heavy reliance on expensive labora-
tory equipment for inducing RBC sickling, device operation and performing the
measurements.
The presence of a small, yet significant fraction of dense RBCs (a result of loss of K+ content
and cellular dehydration) is another hallmark of SCA[29] that has been used as the basis for a
potentially low-cost diagnostic method (dubbed SCD-AMPS).[30, 31] Unlike our paper-based
test, the SCD-AMPS test is not equipment- and electricity-free because it requires centrifuga-
tion of the blood sample placed on a column of density gradient medium to isolate the small
fraction of dense RBCs and render the diagnosis.[30] The most current published version of
the SCD-AMPS test kit includes specially modified capillaries containing the density gradient
medium, a centrifuge and a car battery needed to power the centrifuge,[31] although slower,
manual centrifuges could likely be used instead of a conventional microcentrifuge.[32] A recent
field evaluation of the SCD-AMPS test in a large case-control study conducted in Zambia
revealed that the diagnostic accuracy of the test was significantly diminished by high levels of
HbF, clotting of the blood sample, variation between batches of the specially modified capillar-
ies and the density gradient medium, and the environmental conditions during shipping of the
special capillaries. Unlike our paper-based test, the SCD-AMPS test could not differentiate
between normal individuals (HbAA) and sickle trait carriers (HbAS). The SCD-AMPS test was
able to identify SCA patients (HbSS) with a sensitivity of 86% (82–90%) and a specificity of
only 60% (53–67%),[31] demonstrating diagnostic accuracy that is substantially lower than our
paper-based test. Although earlier reports suggested that SCD-AMPS test could also differenti-
ate between SCA (HbSS) and HbSC disease, unfortunately none of the patients in the Zambia
study had HbSC and therefore it was not possible substantiate this important capability in the
field.[31]
RBCs containing HbS are known to undergo hemolysis when deoxygenated in isotonic solu-
tions of certain non-electrolytes because of the changes in RBC membrane caused by deoxy-
HbS polymerization.[33] A diagnostic test based on monitoring RBC hemolysis in non-
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electrolyte solutions has been proposed for diagnosing SCA.[34] However, complicated sample
preparation, lengthy incubation time, the need for precise control of pH and gasses, and the
specialized equipment needed to interpret the results (by quantifying the change in optical den-
sity), could make this test difficult to use in a resource-limited setting.
Finally, a conventional lateral flow immunoassay for diagnosing SCD at the point-of-care
has recently been developed (dubbed Sickle SCAN™).[35] This test uses proprietary antibodies
to identify the presence of HbA, HbS and HbC within a whole blood sample, and thereby diag-
nose HbAA, HbAS, HbSS, HbSC and HbSβ+-thalassemia. Initial evaluation of the test in a con-
trolled environment of a clinical laboratory and in a clinic in the U.S. has demonstrated
excellent diagnostic accuracy in a population of adults and children older than 5 weeks of age.
[35] According to the Sickle SCAN™ product insert, the test must be stored and used within a
relatively narrow range of temperature (2–30°C), which may preclude the use of this test in
resource-limited settings where temperature cannot be precisely regulated. The presence of
antibodies in this lateral flow test also suggests that the test may have a relatively short shelf
life,[36] however this value has not yet been reported. Additionally, the lateral flow test is quali-
tative and does not have the capacity to quantify HbS concentration (unlike the paper-based
test presented here)[37] and therefore would not be useful for monitoring the effect of
hydroxyurea and transfusion therapies. All of these potential issues notwithstanding, the lateral
flow immunoassay could become a very useful confirmatory test, if the per-test total cost of the
assay could be reduced below the cost of IEF, HE or HPLC performed currently as a standard
of care.
There are two main limitations to the diagnostic capabilities of the paper-based test in its
current form. The first limitation is that the test cannot accurately distinguish between patients
with the HbSC form of sickle cell disease and those with sickle trait (HbAS) either based on
visual scoring (Fig 4A) or the values of S-index (Fig 5A), because both HbSC and HbAS sam-
ples have similar levels of HbS (Fig 4C). We anticipate therefore that the utility of our paper-
based test (as well as any other test relying solely on quantifying %HbS for the diagnosis of
sickle cell disease) may be limited in Burkina Faso and surrounding countries of Central West
Africa, where HbSC disease is most prevalent.[38] An important advantage of our assay, how-
ever, is that if digital images of the blood stains are acquired they can be analyzed in a number
of ways to improve diagnostic accuracy. To demonstrate this capability, we devised the C-
index that enabled us to distinguish between HbAS and HbSC within the group of heterozy-
gous sickle cell trait carriers with sensitivity of 100% and specificity of 59% (Fig 5B and 5C).
Such a high sensitivity, but relatively low specificity, means that C-index could be used to effec-
tively screen out patients who do not have HbSC (negatives), but would necessitate confirma-
tory testing for patients who score positive to make a definitive diagnosis of HbSC. We also
note that although hard threshold values were used for the purpose of evaluating sensitivity
and specificity, a C-index close to the threshold values or the detection of any level of HbS in
samples from patients with a high index of suspicion of SCA of some type could trigger more
detailed testing by IEF or HPLC. Additionally, while automated image analysis to determine S-
and C-index represents an additional layer of complexity to the performance of the test, it also
offers significant advantages: the elimination of subjectivity in test scoring; the capacity for
automated transmission and entry of results into a centralized database; and, when necessary,
the quantitation of sickle hemoglobin levels[18] to guide therapeutic decision-making. Even-
tual adaptation of our automated test-scoring algorithm into software for camera-equipped
and internet-capable portable devices (e.g., smart phones, tablets) could make such automated
analysis feasible in remote settings and make it a significant asset in large-scale public health
screening campaigns.
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The second limitation of our current assay relates to its application in testing neonates and
infants<12 month old. During gestation, 90–95% of all produced hemoglobin molecules are
fetal hemoglobin (HbF), which is unaffected by the sickle mutation. Hemoglobin production
switches to predominantly adult variants after 34–36 weeks of fetal development, and the frac-
tion of HbF declines precipitously, reaching adult levels by age 8–12 months.[39, 40] At birth,
the cord blood of normal newborns (HbAA) contains 14.3 ± 5.3% HbA, while blood of sickle
cell trait carriers (HbAS) contains 9.5 ± 4.2% HbA and 6.5 ± 2.8% HbS, and blood of those
with SCA (HbSS) contains 10.2 ± 3.9% HbS. The version of our paper-based test presented
here is not capable of detecting these low levels of HbS present in blood of newborns and
infants, limiting the usefulness of the test for the identification of SCA or sickle trait in this age
group. To address this limitation, we are currently developing a newborn-specific version of
our paper-based SCA test for rapid, highly sensitive detection of low levels of HbS in neonatal
samples. Automated reading of neonatal and infant samples, as described above, could further
increase the overall sensitivity of the test for HbS. While these improvements are unlikely to
make a truly definitive diagnosis of newborns possible, a low-cost paper-based test sensitive to
the low levels of HbS could facilitate rapid, inexpensive and efficient testing of large numbers
of infants to screen out those negative for HbS, thus limiting expensive definitive testing (via
IEF, HE or HPLC) and efforts to ensure follow-up care to the significantly smaller HbS-positive
cohort.
In summary, we have refined and validated our previously developed paper-based assay for
rapid, low-cost diagnostics of SCA at the point-of-care. We have demonstrated that the test
can be used for the rapid and accurate diagnosis of sickle trait carriers and individuals with
SCA (HbSS, HbSβ+-thalassemia) and, to a more limited extent, individuals with the HbSC
form of sickle cell disease. We have also demonstrated that the test can be performed by novice
healthcare workers in a resource-limited clinical setting. This simple, rapid and low-cost diag-
nostic test represents a major step towards enabling universal screening of children and adults
for SCA in sub-Saharan Africa and other resource-limited settings.
Supporting Information
S1 Fig. Dependence of the blood stain pattern on the HbS content (%HbS) in the sample
for three different formulations of the Hb solubility buffer containing 5, 30 or 100 g/L of
sodium hydrosulfite ([Na2S2O4]).HbAA and HbSS blood samples (matched for ABO-Rh
blood type and hemoglobin concentration) were mixed to artificially create samples with %
HbS ranging from 0 to 75%.
(TIF)
S2 Fig. Dependence of S-index on %HbS for three different formulations of the Hb solubil-
ity buffer containing 5, 30 or 100 g/L of sodium hydrosulfite. Four HbSS samples of known
%HbS ((♦) HbS = 83.7%, [Hb] = 7.9 g/dL; (▲) HbS = 90.0%, [Hb] = 8.2 g/dL; (●) HbS = 88.4%,
[Hb] = 9.1 g/dL; (■) HbS = 74.9%, [Hb] = 10.5 g/dL) were diluted with HbAA blood (matched
for blood type and [Hb]) in ratios of 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9 and 0:10 (by vol-
ume) to create a range of reconstituted blood samples of known %HbS. The S-index for each
reconstituted blood sample was measured using the three formulations of the Hb solubility
buffer. The slope of linear fit was 12.1 for [Na2S2O4] = 30 g/L, in comparison to 6.8 HbS for
[Na2S2O4] = 5 g/L and 15.9 HbS for [Na2S2O4] = 100 g/L. The standard deviation of the differ-
ence between the calculated and true %HbS was 6.4%HbS for [Na2S2O4] = 30 g/L, in compari-
son to 8.4%HbS for [Na2S2O4] = 5 g/L and 6.6%HbS for [Na2S2O4] = 100 g/L.
(TIF)
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S3 Fig. Variation of S-index due to imperfect metering of liquid volumes.Data shown as
mean ± standard deviation (n = 5 blood stains per sample). (a) S-index measured for blood
mixed with Hb solubility buffer at 1:8, 1:9, 1:10, 1:11 and 1:12 ratios by volume (droplet volume
20 μL). (b) S-index measured for 16 μL, 18 μL, 20 μL, 22 μL and 24 μL droplets of the mixture
of blood and Hb solubility buffer (1:10 ratio, by volume).
(TIF)
S4 Fig. Effect of delay in reading time and storage of blood samples. (a, b) Short-term stabil-
ity of paper-based SCA assay measurements was evaluated by scanning the sheets of paper con-
taining the blood stains repeatedly over (a) 1 hour and (b) 24 hours after the samples were
deposited on paper (HbSS (■), HbAS (▲) and HbAA (●)). The shaded area in (b) outlines the
data shown in (a). (c) S-index was measured daily for blood samples stored over a one week
storage period. The error bars represent one standard deviation from the average of SCD assay
measurements performed by 4 different technicians.
(TIF)
S5 Fig. Supplementary Figure S5. Sample collection and classification flowchart for the
Angola site.
(TIF)
S1 Methods. Description of methods used to produce data for supplementary figures.
(DOCX)
S1 Minimal Dataset. The minimal data set underlying the findings reported in our study.
(XLSX)
S1 Table. Shows a breakdown of the costs of the paper-based test components.
(DOCX)
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